|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Aus G, Damber JE, Khatami A, Lilja H,
Stranne J and Hugosson J: Individualized screening interval for
prostate cancer based on prostate-specific antigen level: Results
of a prospective, randomized, population-based study. Arch Intern
Med. 165:1857–1861. 2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Thompson IM, Pauler DK, Goodman PJ, Tangen
CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford
ED, et al: Prevalence of prostate cancer among men with a
prostate-specific antigen level < or =4.0 ng per milliliter. N
Engl J Med. 350:2239–2246. 2004.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Schroder FH, van der Cruijsen-Koeter I, de
Koning HJ, Vis AN, Hoedemaeker RF and Kranse R: Prostate cancer
detection at low prostate specific antigen. J Urol. 163:806–812.
2000.
|
|
5
|
Antenor JA, Han M, Roehl KA, Nadler RB and
Catalona WJ: Relationship between initial prostate specific antigen
level and subsequent prostate cancer detection in a longitudinal
screening study. J Urol. 172:90–93. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Botchorishvili G, Matikainen MP and Lilja
H: Early prostate-specific antigen changes and the diagnosis and
prognosis of prostate cancer. Curr Opin Urol. 19:221–226.
2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Schröder FH, Hugosson J, Carlsson S,
Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F and
Roobol MJ: Screening for prostate cancer decreases the risk of
developing metastatic disease: Findings from the European
Randomized Study of Screening for Prostate Cancer (ERSPC). Eur
Urol. 62:745–752. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Heidenreich A, Abrahamsson PA, Artibani W,
Catto J, Montorsi F, Van Poppel H, Wirth M and Mottet N: European
Association of Urology: Early detection of prostate cancer:
European Association of Urology recommendation. Eur Urol.
64:347–354. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kilmer G, Roberts H, Hughes E, Li Y,
Valluru B, Fan A, Giles W, Mokdad A and Jiles R: Centers for
Disease Control and Prevention (CDC): Surveillance of certain
health behaviors and conditions among states and selected local
areas-Behavioral Risk Factor Surveillance System (BRFSS), United
States, 2006. MMWR Surveill Summ. 57:1–188. 2008.PubMed/NCBI
|
|
10
|
Nagamani SC and Erez A: A metabolic link
between the urea cycle and cancer cell proliferation. Mol Cell
Oncol. 3(e1127314)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Keshet R, Szlosarek P, Carracedo A and
Erez A: Rewiring urea cycle metabolism in cancer to support
anabolism. Nat Rev Cancer. 18:634–645. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tan P, Shi M, Chen J, Xu H, Xie N, Xu H,
Jiang Y, Ai JZ, Liu LR, Yang L and Wei Q: The preoperative serum
cystatin-C as an independent prognostic factor for survival in
upper tract urothelial carcinoma. Asian J Androl. 21:163–169.
2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Evans TRJ, Kudo M, Finn RS, Han KH, Cheng
AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F and Sung
MW: Urine protein:creatinine ratio vs. 24-hour urine protein for
proteinuria management: Analysis from the phase 3 REFLECT study of
lenvatinib vs. sorafenib in hepatocellular carcinoma. Br J Cancer.
121:218–221. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Selcukbiricik F, Kanbay M, Solak Y, Bilici
A, Kanitez M, Balik E and Mandel NM: Serum uric acid as a surrogate
marker of favorable response to bevacizumab treatment in patients
with metastatic colon cancer. Clin Transl Oncol. 18:1082–1087.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Benli E, Cirakoglu A, Ayyildiz SN and Yüce
A: Comparison of serum uric acid levels between prostate cancer
patients and a control group. Cent European J Urol. 71:242–247.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hashmi A, Cahill GL, Zaldana M, Davis G,
Cronin BJ, Brandel MG, Beletsky A, Taj R, Buckstaff TM, Vinocur D,
et al: Can head circumference be used as a proxy for intracranial
volume in patients with craniosynostosis? Ann Plast Surg. 82 (5S
Suppl 4):S295–S300. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ebert E, Werle B, Jülke B, Kopitar-Jerala
N, Kos J, Lah T, Abrahamson M, Spiess E and Ebert W: Expression of
cysteine protease inhibitors stefin A, stefin B, and cystatin C in
human lung tumor tissue. Adv Exp Med Biol. 421:259–265.
1997.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Friedrich B, Jung K, Lein M, Türk I,
Rudolph B, Hampel G, Schnorr D and Loening SA: Cathepsins B, H, L
and cysteine protease inhibitors in malignant prostate cell lines,
primary cultured prostatic cells and prostatic tissue. Eur J
Cancer. 35:138–144. 1999.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wegiel B, Jiborn T, Abrahamson M,
Helczynski L, Otterbein L, Persson JL and Bjartell A: Cystatin C is
downregulated in prostate cancer and modulates invasion of prostate
cancer cells via MAPK/Erk and androgen receptor pathways. PLoS One.
4(e7953)2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Weinstein SJ, Mackrain K,
Stolzenberg-Solomon RZ, Selhub J, Virtamo J and Albanes D: Serum
creatinine and prostate cancer risk in a prospective study. Cancer
Epidemiol Biomarkers Prev. 18:2643–2649. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang M, Zou L, Liang J, Wang X, Zhang D,
Fang Y, Zhang J, Xiao F and Liu M: The urinary sarcosine/creatinine
ratio is a potential diagnostic and prognostic marker in prostate
cancer. Med Sci Monit. 24:3034–3041. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kolonel LN, Yoshizawa C, Nomura AM and
Stemmermann GN: Relationship of serum uric acid to cancer
occurrence in a prospective male cohort. Cancer Epidemiol
Biomarkers Prev. 3:225–228. 1994.PubMed/NCBI
|
|
23
|
Ames BN, Cathcart R, Schwiers E and
Hochstein P: Uric acid provides an antioxidant defense in humans
against oxidant- and radical-caused aging and cancer: A hypothesis.
Proc Natl Acad Sci USA. 78:6858–6862. 1981.PubMed/NCBI View Article : Google Scholar
|
